End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation
Frontiers in Cellular and Infection Microbiology · 2023
DOI: 10.3389/fcimb.2023.1120300 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Yifei Guo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Institute of Infectious …. Hauptthemen laut MEDLINE: Hepatitis B Surface Antigens, Hepatitis B, Chronic. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Hepatitis B surface antigen (HBsAg) loss, namely, the functional cure, can be achieved through the pegylated interferon (PEG-IFN)-based therapy. However, it is an unignorable fact that a small proportion of patients who achieved functional cure develop HBsAg reversion (HRV) and the related factors are not well described.
Methods
A total of 112 patients who achieved PEG-IFN-induced HBsAg loss were recruited. HBV biomarkers and biochemical parameters were examined dynamically. HBV RNA levels were assessed in the cross-sectional analysis. The primary endpoint was HRV, defined as the reappearance of HBsAg after PEG-IFN discontinuation.
Results
HRV occurred in 17 patients during the follow-up period. Univariable analysis indicated that hepatitis B e antigen (HBeAg) status, different levels of hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc) at the end of PEG-IFN treatment (EOT) were significantly associated with the incidence of HRV through using the log-rank test. Additionally, time-dependent receiver operating characteristic (ROC) analysis showed that the anti-HBs was superior to anti-HBc in predictive power for the incidence of HRV during the follow-up period. Multivariable Cox proportional hazard analysis found that anti-HBs ≥1.3 log 10 IU/L (hazard ratio (HR), 0.148; 95% confidence interval (CI), 0.044-0.502) and HBeAg negativity (HR, 0.183; 95% CI, 0.052-0.639) at EOT were independently associated with lower incidence of HRV. Cross-sectional analysis indicated that the HBV RNA levels were significantly correlated with the HBsAg levels in patients with HRV (r=0.86, p=0.003).
Conclusions
EOT HBeAg negativity and anti-HBs ≥1.3 log 10 IU/L identify the low risk of HRV after PEG-IFN discontinuation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Institute of Infectious Diseases and Biosecurity, National Medical Center for Infectious Disea…
- Department of Medical Microbiology and Parasitology, School of Medical Sciences, Fudan University, Shanghai, China.
- Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Sh…
- Department of Infectious Diseases, Jing'An Branch of Huashan Hospital, Fudan University, Shanghai, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Guo, Y., Han, J., Zhang, Y., Jin, C., Zhang, Y., He, J., Chen, S., Guo, Y., Lin, Y., Li, F., Yang, F., Shen, Z., Mao, R., Zhu, H., & Zhang, J. (2023). End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1120300
Vancouver
Guo Y, Han J, Zhang Y, Jin C, Zhang Y, He J, et al. End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2023.1120300
BibTeX
@article{Guo2023,
author = {Guo, Yifei and Han, Jiajia and Zhang, Yongmei and Jin, Chengmeng and Zhang, Yao and He, Jingjing and Chen, Shiqi and Guo, Yue and Lin, Yanxue and Li, Fahong and Yang, Feifei and Shen, Zhongliang and Mao, Richeng and Zhu, Haoxiang and Zhang, Jiming},
title = {End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2023},
doi = {10.3389/fcimb.2023.1120300}
}
EUVIMED